{"schemaVersion":"peptidescanner-clinical-trials-history-object/v1","objectId":"clinical-trials-history:NCT03375788","recordId":"NCT03375788","peptideSlug":"tesamorelin","publishedAt":"2026-08-23","sourceObservedAt":"2026-08-23T23:32:33.000Z","sourceObservationSha256":"6ae8058d20bbb511d9250d19ac0bd3475945bb56f0057fdb437648218b72606e","urls":{"human":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03375788-tesamorelin/","json":"https://peptidescanner.com/clinical-trials-history/v1/trials/nct03375788.json","markdown":"https://peptidescanner.com/clinical-trials-history/v1/trials/nct03375788.md"},"reportingBoundary":"ClinicalTrials.gov lists this public record-history version and identifies its submitted date and the source modules marked as changed. PeptideScanner does not infer what changed inside a module, why it changed, whether the change is material, whether the study is trustworthy, or whether an intervention is safe or effective.","versions":[{"changedModules":[],"historyVersion":1,"lastUpdateSubmitQcDate":"2017-12-13","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"NOT_YET_RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2017-12-13","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"f29ddafb86ac33f4f800e50592be16645a05af9fe21e4bb0c31e732c4d87e262","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=1&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Arms and Interventions","Conditions","Outcome Measures","Study Status"],"historyVersion":2,"lastUpdateSubmitQcDate":"2017-12-15","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"NOT_YET_RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2017-12-15","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"9117437b792f307424d986653641ec22bd6dbd549eaa4b65e9ff5093d206eca6","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=2&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Study Status"],"historyVersion":3,"lastUpdateSubmitQcDate":"2018-08-14","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"NOT_YET_RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2018-08-14","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"4f8a9d127855547d30fbda728f17cc25101035dc69f8acc1ee46c632bef7d731","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=3&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Sponsor/Collaborators","Study Status"],"historyVersion":4,"lastUpdateSubmitQcDate":"2018-10-19","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"NOT_YET_RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2018-10-19","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"b7315ca1cefd241efc7d0949da64519ece42c7b51156a99e40ebed4b3c6cdf1f","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=4&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Contacts/Locations","Outcome Measures","Sponsor/Collaborators","Study Status"],"historyVersion":5,"lastUpdateSubmitQcDate":"2019-02-21","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2019-02-21","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"5228676b5e5d0d95c5e9d1173d0731cf83c1f9907f17df52bafb851c9a9b1cec","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=5&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Arms and Interventions","Eligibility","Study Status"],"historyVersion":6,"lastUpdateSubmitQcDate":"2019-11-19","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2019-11-19","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"431b08e31e2f8eb4ee344d1d1cd1f013bbe0bf53016e802b1e9787054b27a4f3","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=6&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Study Status"],"historyVersion":7,"lastUpdateSubmitQcDate":"2021-03-29","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2021-03-29","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"6055a576b9bcce373580c16a15e1be38e2e119e8846d74ff28dbd7d6458d0c80","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=7&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Study Status"],"historyVersion":8,"lastUpdateSubmitQcDate":"2022-08-11","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2022-08-11","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"500abdd7cad92b58eabac23d8084a163fb1402ede4c10e0feff6a68960fb3e6e","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=8&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Contacts/Locations","Study Status"],"historyVersion":9,"lastUpdateSubmitQcDate":"2023-05-29","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"ACTIVE_NOT_RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2023-05-29","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"5210e37bebab0d9673932c40b4902933a709f7f9d2aa06368974c7a37ad182c0","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=9&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Oversight","Study Status"],"historyVersion":10,"lastUpdateSubmitQcDate":"2024-09-11","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"ACTIVE_NOT_RECRUITING","peptideSlug":"tesamorelin","submittedDate":"2024-09-11","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"7d6b65e6e69d2998a244a444c10068f395d048fdaee51e1555fe3b6b68670ac4","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=10&tab=history","studyType":"INTERVENTIONAL"},{"changedModules":["Adverse Events","Outcome Measures","Outcome Measures (Results)","Study Status"],"historyVersion":14,"lastUpdateSubmitQcDate":"2025-11-06","observedAt":"2026-08-23T23:32:33.000Z","overallStatus":"COMPLETED","peptideSlug":"tesamorelin","submittedDate":"2025-11-06","publishedAt":"2026-08-23","recordId":"NCT03375788","recordSha256":"96f23bb33b391960f901b9ca8a45c8936b23118896ef6cd7f66df5a5e5d74c62","schemaVersion":"tier-a-clinicaltrials-gov-history-public-record/v1","sourceUrl":"https://clinicaltrials.gov/study/NCT03375788?a=14&tab=history","studyType":"INTERVENTIONAL"}],"integrity":{"algorithm":"sha256","contentSha256":"b741cc742c4575d93a7ad3f00397e3bee3cb0c5a3964810744b8bf891a2f4bd9"}}